+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-10-26Number of Pages: 183

Human Vaccines Market (Vaccine Type - Conjugate, Recombinant, Inactivated, Combination, and Attenuated; Product - Pneumococcal, Influenza, Hepatitis, HPV, Meningococcal, Rotavirus, Measles, Typhoid, and Combination; Age Group - Pediatrics, Adolescents, Adults, and Geriatrics; Distribution Channel - Hospital Pharmacies and Drugstores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

1. Preface
     1.1. Research Scope     
     1.2. Market Segmentation
     1.3. Research Objectives
     1.4. Key Questions Answered

2. Assumptions and Research Methodology
     2.1. Report Assumptions
     2.2. Acronyms Used
     2.3. Research Methodology

3. Executive Summary
     3.1. Global Human Vaccines Market Snapshot
     3.2. Market Opportunity Map

4. Market Overview
     4.1. Product Overview
     4.2. Key Industry Events
     4.3. Emerging Trend in Human Vaccines Market

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis
     5.2. Drivers
     5.3. Restraints
     5.4. Opportunities
     5.5. Opportunity Analysis

6. Global Human Vaccines Market Analysis, by Vaccine Type
     6.1. Key Findings
     6.2. Introduction
     6.3. Conjugate
     6.4. Recombinant
     6.5. Conjugate Vaccines
     6.6. Inactivated
     6.7. Combination
     6.8. Attenuated
     6.9. Others
     6.10. Key Trends
     6.11. Market Attractiveness Analysis, by Vaccine Type, 2015

7. Global Human Vaccines Market Analysis, by Product
     7.1. Key Findings
     7.2. Introduction
     7.3. Pneumococcal
     7.4. Influenza
     7.5. Hepatitis
     7.6. HPV
     7.7. Meningococcal
     7.8. Rotavirus
     7.9. Measles and Rubella
     7.10. Typhoid
     7.11. Combination
     7.12. Others
     7.13. Key Trend Analysis

8. Global Human Vaccines Market Analysis, by Distribution Channel
     8.1. Key Findings
     8.2. Introduction
     8.3. Hospital Pharmacies
     8.4. Drugstores
     8.5. Others
     8.6. Key Trend Analysis
     8.7. Market Attractiveness Analysis

9. Global Human Vaccines Market Analysis, by Age Group
     9.1. Key Findings
     9.2. Introduction
     9.3. Pediatrics
     9.4. Adolescents
     9.5. Adults
     9.6. Geriatrics
     9.7. Key Trend Analysis
     9.8. Market Attractiveness Analysis

10. Global Human Vaccines Market Analysis, by Region
     10.1. North America
     10.2. Europe
     10.3. Asia Pacific
     10.4. Latin America
     10.5. Middle East & Africa

11. North America Human Vaccines Market Analysis
     11.1. North America Human Vaccines Market Size Forecast, By Country, 2016-2024
     11.2. North America Human Vaccines Market Size Forecast, By Product, 2016-2024
     11.3. North America Human Vaccines Market Size Forecast, By Vaccine Type, 2016-2024
     11.4. North America Human Vaccines Market Size Forecast, By Age Group, 2016-2024
     11.5. North America Human Vaccines Market Size Forecast, By Distribution Channel, 2016-2024
     11.6. North America Human Vaccines Market Attractiveness Analysis, 2016-2024

12. Europe Human Vaccines Market Analysis
     12.1. Europe Human Vaccines Market Size Forecast, By Country, 2016-2024
     12.2. Europe Human Vaccines Market Size Forecast, By Product, 2016-2024
     12.3. Europe Human Vaccines Market Size Forecast, By Vaccine Type, 2016-2024
     12.4. Europe Human Vaccines Market Size Forecast, By Age Group, 2016-2024
     12.5. Europe Human Vaccines Market Size Forecast, By Distribution Channel, 2016-2024
     12.6. Europe Human Vaccines Market Attractiveness Analysis, 2016-2024

13. Asia Pacific Human Vaccines Market Analysis
     13.1. Asia Pacific Human Vaccines Market Size Forecast, By Country, 2016-2024
     13.2. Asia Pacific Human Vaccines Market Size Forecast, By Product, 2016-2024
     13.3. Asia Pacific Human Vaccines Market Size Forecast, By Vaccine Type, 2016-2024
     13.4. Asia Pacific Human Vaccines Market Size Forecast, By Age Group, 2016-2024
     13.5. Asia Pacific Human Vaccines Market Size Forecast, By Distribution Channel, 2016-2024
     13.6. Asia Pacific Human Vaccines Market Attractiveness Analysis, 2016-2024

14. Latin America Human Vaccines Market Analysis
     14.1. Latin America Human Vaccines Market Size Forecast, By Country, 2016-2024
     14.2. Latin America Human Vaccines Market Size Forecast, By Product, 2016-2024
     14.3. Latin America Human Vaccines Market Size Forecast, By Vaccine Type, 2016-2024
     14.4. Latin America Human Vaccines Market Size Forecast, By Age Group, 2016-2024
     14.5. Latin America Human Vaccines Market Size Forecast, By Distribution Channel, 2016-2024
     14.6. Latin America Human Vaccines Market Attractiveness Analysis, 2016-2024

15. Middle East & Africa Human Vaccines Market Analysis
     15.1. Middle East & Africa Human Vaccines Market Size Forecast, By Country, 2016-2024
     15.2. Middle East & Africa Human Vaccines Market Size Forecast, By Product, 2016-2024
     15.3. Middle East & Africa Human Vaccines Market Size Forecast, By Vaccine Type, 2016-2024
     15.4. Middle East & Africa Human Vaccines Market Size Forecast, By Age Group, 2016-2024
     15.5. Middle East & Africa Human Vaccines Market Size Forecast, By Distribution Channel, 2016-2024
     15.6. Middle East & Africa Human Vaccines Market Attractiveness Analysis, 2016-2024

16. Competitive Landscape
     16.1. Human Vaccines Market Share Analysis By Company (2015)
     16.2. Competition Matrix

17. Company Profiles
     17.1. AstraZeneca
            17.1.1. Company Details
            17.1.2. Company Description
            17.1.3. Business Overview
            17.1.4. SWOT Analysis
            17.1.5. Financial Analysis
            17.1.6. Strategic Overview
     17.2. Bavarian Nordic
            17.2.1. Company Details
            17.2.2. Company Description
            17.2.3. Business Overview
            17.2.4. SWOT Analysis
            17.2.5. Financial Analysis
            17.2.6. Strategic Overview
     17.3. Bharat Biotech
            17.3.1. Company Details
            17.3.2. Company Description
            17.3.3. Business Overview
            17.3.4. SWOT Analysis
            17.3.5. Financial Analysis
            17.3.6. Strategic Overview
     17.4. CSL Limited
            17.4.1. Company Details
            17.4.2. Company Description
            17.4.3. Business Overview
            17.4.4. SWOT Analysis
            17.4.5. Financial Analysis
            17.4.6. Strategic Overview
     17.5. Emergent BioSolutions, Inc.
            17.5.1. Company Details
            17.5.2. Company Description
            17.5.3. Business Overview
            17.5.4. SWOT Analysis
            17.5.5. Financial Analysis
            17.5.6. Strategic Overview
     17.6. GlaxoSmithKline plc
            17.6.1. Company Details
            17.6.2. Company Description
            17.6.3. Business Overview
            17.6.4. SWOT Analysis
            17.6.5. Financial Analysis
            17.6.6. Strategic Overview
     17.7. Johnson & Johnson
            17.7.1. Company Details
            17.7.2. Company Description
            17.7.3. Business Overview
            17.7.4. SWOT Analysis
            17.7.5. Financial Analysis
            17.7.6. Strategic Overview
     17.8. Merck & Co., Inc.
            17.8.1. Company Details
            17.8.2. Company Description
            17.8.3. Business Overview
            17.8.4. SWOT Analysis
            17.8.5. Financial Analysis
            17.8.6. Strategic Overview
     17.9. Mymetics
            17.9.1. Company Details
            17.9.2. Company Description
            17.9.3. Business Overview
            17.9.4. SWOT Analysis
            17.9.5. Financial Analysis
            17.9.6. Strategic Overview
     17.10. Novartis AG
            17.10.1. Company Details
            17.10.2. Company Description
            17.10.3. Business Overview
            17.10.4. SWOT Analysis
            17.10.5. Financial Analysis
            17.10.6. Strategic Overview
     17.11. Pfizer, Inc.
            17.11.1. Company Details
            17.11.2. Company Description
            17.11.3. Business Overview
            17.11.4. SWOT Analysis
            17.11.5. Financial Analysis
            17.11.6. Strategic Overview
     17.12. Sanofi
            17.12.1. Company Details
            17.12.2. Company Description
            17.12.3. Business Overview
            17.12.4. SWOT Analysis
            17.12.5. Financial Analysis
            17.12.6. Strategic Overview
     17.13. Shenzhen Kangtai Biological Products Co., Ltd.
            17.13.1. Company Details
            17.13.2. Company Description
            17.13.3. Business Overview
            17.13.4. SWOT Analysis
            17.13.5. Financial Analysis
            17.13.6. Strategic Overview
     17.14. Takeda Pharmaceutical Company Limited.
            17.14.1. Company Details
            17.14.2. Company Description
            17.14.3. Business Overview
            17.14.4. SWOT Analysis
            17.14.5. Financial Analysis
            17.14.6. Strategic Overview

List of Figures

FIG. 1 Global Human Vaccines Market Value Share Analysis, by Vaccine Type, 2015 and 2024
FIG. 2 Global Conjugate Market Revenue (US$ Mn), 2014–2024
FIG. 3 Global Recombinant Market Revenue (US$ Mn), 2014–2024
FIG. 4 Global Inactivated Market Revenue (US$ Mn), 2014–2024
FIG. 5 Global Combination Market Revenue (US$ Mn), 2014–2024
FIG. 6 Global Attenuated Market Revenue (US$ Mn), 2014–2024
FIG. 7 Global Others Market Revenue (US$ Mn), 2014–2024
FIG. 8 Human Vaccines Market Attractiveness Analysis, by Vaccine Type, 2015
FIG. 9 Global Human Vaccines Market Value Share Analysis, by Product, 2015 and 2024
FIG. 10 Global Pneumococcal Market Revenue (US$ Mn), 2014–2024
FIG. 11 Global Influenza Market Revenue (US$ Mn), 2014–2024
FIG. 12 Global Hepatitis Market Revenue (US$ Mn), 2014–2024
FIG. 13 Global HPV Market Revenue (US$ Mn), 2014–2024
FIG. 14 Global Meningococcal Market Revenue (US$ Mn), 2014–2024
FIG. 15 Global Rotavirus Market Revenue (US$ Mn), 2014–2024
FIG. 16 Global Measles and Rubella Market Revenue (US$ Mn), 2014–2024
FIG. 17 Global Typhoid Market Revenue (US$ Mn), 2014–2024
FIG. 18 Global Combination Market Revenue (US$ Mn), 2014–2024
FIG. 19 Global Others Market Revenue (US$ Mn), 2014–2024
FIG. 20 Human Vaccines Market Attractiveness Analysis, by Product, 2015
FIG. 21 Global Human Vaccines Market Value Share Analysis, by Distribution Channel, 2015 and 2024
FIG. 22 Global Hospital Pharmacies Market Revenue (US$ Mn), 2014–2024
FIG. 23 Global Drugstores Market Revenue (US$ Mn), 2014–2024
FIG. 24 Global others Market Revenue (US$ Mn), 2014–2024
FIG. 25 Human Vaccines Market Attractiveness Analysis, by Distribution Channel, 2015
FIG. 26 Global Human Vaccines Market Value Share Analysis, by Age Group, 2015 and 2024
FIG. 27 Global Pediatrics Market Revenue (US$ Mn), 2014–2024
FIG. 28 Global Adolescents Market Revenue (US$ Mn), 2014–2024
FIG. 29 Global Adults Market Revenue (US$ Mn), 2014–2024
FIG. 30 Global Geriatrics Market Revenue (US$ Mn), 2014–2024
FIG. 31 Human Vaccines Market Attractiveness Analysis, by Age Group, 2015
FIG. 32 North America Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 33 Europe Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 34 APAC Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 35 Latin America Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 36 MEA Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 37 Global Human Vaccines Market Attractiveness Analysis, by Region
FIG. 38 China Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 39 Japan Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 40 ASEAN Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 41 Rest of APAC Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 42 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Country
FIG. 43 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Product
FIG. 44 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Vaccine Type
FIG. 45 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Age Group
FIG. 46 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Distribution Channel
FIG. 47 U.S. Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 48 Canada Human Vaccines Market Size (US$ Mn) Forecast, 2016–202
FIG. 49 North America Human Vaccines Market Attractiveness Analysis, by Country
FIG. 50 North America Human Vaccines Market Attractiveness Analysis, by Product
FIG. 51 North America Human Vaccines Market Attractiveness Analysis, by Vaccine Type
FIG. 52 North America Human Vaccines Market Attractiveness Analysis, by Age Group
FIG. 53 North America Human Vaccines Market Attractiveness Analysis, by Distribution Channel
FIG. 54 Germany Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 55 France Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 56 U.K. Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 57 Italy Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 58 Spain Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 59 Rest of Europe Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 60 Europe Human Vaccines Market Attractiveness Analysis, by Country
FIG. 61 Europe Human Vaccines Market Attractiveness Analysis, by Product
FIG. 62 Europe Human Vaccines Market Attractiveness Analysis, by Vaccine Type
FIG. 63 Europe Human Vaccines Market Attractiveness Analysis, by Age Group
FIG. 64 Europe Human Vaccines Market Attractiveness Analysis, by Distribution Channel
FIG. 65 Brazil Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 66 Mexico Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 67 Rest of LATAM Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 68 Latin America Human Vaccines Market Attractiveness Analysis, by Country
FIG. 69 Latin America Human Vaccines Market Attractiveness Analysis, by Product
FIG. 70 Latin America Human Vaccines Market Attractiveness Analysis, by Vaccine Type
FIG. 71 Latin America Human Vaccines Market Attractiveness Analysis, by Age Group
FIG. 72 Latin America Human Vaccines Market Attractiveness Analysis, by Distribution Channel
FIG. 73 GCC Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 74 South Africa Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 75 Rest of MEA Human Vaccines Market Size (US$ Mn) Forecast, 2016–2024
FIG. 76 MEA Human Vaccines Market Attractiveness Analysis, by Country
FIG. 77 MEA Human Vaccines Market Attractiveness Analysis, by Product
FIG. 78 MEA Human Vaccines Market Attractiveness Analysis, by Vaccine Type
FIG. 79 MEA Human Vaccines Market Attractiveness Analysis, by Age Group
FIG. 80 MEA Human Vaccines Market Attractiveness Analysis, by Distribution Channel
FIG. 81 Human Vaccine Market Share Analysis, by Company (2015)

List of Tables

TABLE 1 Global Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2016–2024
TABLE 2 Global Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 3 Global Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 4 Global Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 5 Global Human Vaccines Market Size (US$ Mn) Forecast, by Region, 2016–2024
TABLE 6 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 7 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 8 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2016–2024
TABLE 9 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 10 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 11 North America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 12 North America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 13 North America Human Vaccines Market Size (US$) Forecast, by Vaccine Type, 2016–2024
TABLE 14 North America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 15 North America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 16 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 17 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 18 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2016–2024
TABLE 19 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 20 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 21 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 22 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 23 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2016–2024
TABLE 24 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 25 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 26 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 27 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2016–2024
TABLE 28 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2016–2024
TABLE 29 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2016–2024
TABLE 30 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024


 
 
Back To Top